LISCure Biosciences Inc.
LISCure Biosciences Provides Novel Therapeutics to Patients with Refractory Diseases Using the LMT Platform. LISCure is developing the world’s first injectable immuno-oncology program using non-pathogenic microorganisms. We focus on the development of first-in-class new drugs against diseases for which existing microbiome treatments have been rarely attempted. We are developing therapeutics for diseases with high unmet medical needs, such as immuno-oncology, metabolic diseases, autoimmune diseases, and neurodegenerative diseases, using a single strain and microbial-derived metabolites, extracellular vesicles (EVs) such as exosomes. To continue providing new treatments for patients, we developed the LMT (LISCure Microbiology-based Technology) platform to discover and identify microorganisms that are scientifically proven safe and effective for various therapeutic areas.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About Us
The Great Pioneer for Incurable Diseases
LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”
Bacteria-mediated Cancer Immunotherapy
- Novel Immunotherapy
- Monotherapy
- Complete Remission with a single dose only
LMT Platform
- (LISCure Microbiology-based Technology)
Microbiome Therapeutics
- Liver diseases, autoimmune diseases, neurodegenerative diseases
- Safety assessment (reviewed by FDA)
- Using metabolites (such as EV)
Pipeline
Addressing Areas of High Unmet Medical Needs
- Including Oncology, Liver Diseases, Neuroscience, and Immunology
- We are conducting a number of global clinical trials, and we have partnered with reputable research institutes, such as Mayo Clinic and Scripps Research, to jointly research and develop liver disease and immuno-oncology programs.